Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)

Smith SE, Swanson LA, Wonnaparhown A, DiCaudo DJ, Nelson SA, Kasperkiewicz M. Delayed diagnosis of pemphigus herpetiformis in a patient with dupilumab-associated hypereosinophilia. JAAD Case[...]

Zhang XD, Bai XS, Teng C, Chilukuri S, Teng J, Ablon G, Gold MH. Managing Rosacea with Nanodiamond-zinc Oxide: Real-world Evidence for Reduction in Redness[...]

Armstrong A, Strober B, Gisondi P, Orroth KK, Cordey M, Kent ST, Deignan C, Jardon S, Hernandez RK, Brookhart MA, Stein Gold L. Benefits of[...]